An enzyme-linked immunosorbent assay (ELISA) for the detection of trypanosomal antigens in goat serum using a monoclonal antibody

Trypanosomosis in Goats

Trypanosomosis is a major constraint on ruminant livestock production in Africa, Asia, and South America. The principal host species affected varies geographically, but buffalo, cattle, camels, and horses are particularly sensitive. Natural infections with Trypanosoma congolense, T. vivax, T. brucei, and T. evansi have been described in goats. Trypanosomosis in goats produces acute, subacute, chronic, or subclinical forms, being T. vivax, T. congolense, and T. evansi, the most invasive trypanosomes for goats. However, the role of goats in the epidemiology of trypanosomosis is largely discussed and not well understood. Thus, it has commonly been assumed that trypanosomosis presents a subclinical course and that goats do not play an important role in the epidemiology of the disease. This can partially be due to parasitemia caused by trypanosomes which has been considered low in goats. However, this assumption is currently undergoing a critical reappraisal because of goats may also serve as a reservoir of trypanosome infection for other species, including the human beings in the case of T. brucei rhodesiense. The present article describes the current status of trypanosomosis in goats in Africa, Asia, and South America. Pathogenesis, clinical features, diagnosis, and treatment of the different trypanosomes are also described. The possible role in the epidemiology of the disease in the different areas is also discussed.

Preliminary Evaluation of Diagnostic Tests Using Horses Experimentally Infected with Trypanosoma evansi

Seven surra negative horses were intravenously inoculated with 3 x 10(6)Trypanosoma evansi parasites derived from a camel. One horse was maintained as an uninfected negative control. Three antigen and three antibody detection tests were evaluated for diagnosis of infection in horses. The microhaematocrit centrifugation test (MHCT) was the most sensitive, first detecting parasites between one and three days (x 2.4) post infection (p.i.). The antigen (ag)-ELISA detected antigen between three and ten days (x 6.6) p.i. The latex agglutination test (LAT) first gave positive results on day 3 (x 3.0) p.i. Following the treatment of horses with trypanocidal drugs, the MCHT and the mouse inoculation test (MIT) became negative. Antigen levels using LAT declined and reached pre-infection levels in five out of six horses during the period of observation (92-279 days). Antigen levels using the ag-ELISA declined as well but did not reach pre-infection levels in any of the six horses.Three antibody detection techniques, ab-ELISA, card agglutination test (CATT), and immunofluorescent antibody test (IFAT) detected antibodies in the blood of all seven infected horses but not in the uninfected control. However, the ab-ELISA did not discriminate clearly between sera from infected and uninfected horses because unacceptably high ELISA background readings were detected in 15% of the surra negative horses shipped to the UAE from the UK. The ELISA antibody increased above pre-infection levels in the six horses experimentally infected, but not in one horse. In this horse the ELISA antibody level exceeded the cut-off level only after the reoccurrence of the T. evansi infection. The IFAT detected antibodies 15.7 days p.i. in all infected horses.

Immunoassay of circulating trypanosomal antigens in sleeping sickness patients undergoing treatment

Sera from 99 patients infected with Trypanosoma brucei rhodesiense and undergoing treatment, were analyzed for circulating trypanosomal antigens using a sandwich antigen-trapping enzyme-linked immunosorbent assay (ELISA). Trypanosomal antigens were detected in 83 (84%) of the patients. Post-treatment antigen profile in 67 patients showed five distinct patterns: in 48% of the patients antigen levels remained elevated throughout the time of hospitalisation and follow-up; in 31%, antigens dropped to the negative value by the second month; in 7.5%, antigens dropped to the negative level and became elevated afterwards; in 7.5%, antigen levels were negative initially, but later, became elevated and remained so throughout the observation period; in 6%, antigen levels remained below the negative value throughout. All patients who relapsed on follow-up had earlier shown evidence of elevated antigen profile. There were no cases of relapses among 21 patients whose antigen levels dropped subsequent to treatment. This ELISA trypanosome antigen detection test could be useful in evaluating treatment success, when used together with parasitological diagnostic techniques.

Comparison of antibody- and antigen-detection enzyme immunoassays for the diagnosis of Trypanosoma evansi infections in camels

A total of 183 camels from Kenya were examined for circulating trypanosomal antigens by four methods: (1) a monoclonal antigen-detection enzyme-linked immunosorbent assay (Ag-ELISA) and circulating anti-trypanosomal antibodies; (2) antibody-detection enzyme-linked immunosorbent assay (Ab-ELISA); (3) buffy-coat examination (BCE); (4) mouse subinoculation (MI). Thirty-seven camels (20%) were parasite-positive by BCE and 60 camels (33%) were parasite-positive by MI. Sixty-three camels (34%) tested positive on Ag-ELISA. Of the 24 camels which could not be detected by BCE, Ag-ELISA detected 18 (75%). Ab-ELISA detected 90 (49%) positive camels. Of all the parasite-positive camels (61), Ag-ELISA detected 93% and Ab-ELISA 95%. Based on the results of 55 camels, there was a significant statistical difference (P < 0.0001) in Ag-ELISA optical density (OD) values (of either serum or plasma antigen analysis) between parasite-positive and parasite-negative camels. No significant difference was observed in Ab-ELISA OD values between parasite-positive and parasite-negative camels. Diagnosis of T. evansi infection in camels by the use of Ag-ELISA alone or in combination with BCE could therefore be a more preferred approach in assessing patient infection than the use of Ab-ELISA.